BeiGene Limited (02142.HK) announced that the Phase I clinical trial results of the investigational anti-CTLA-4 fully human monoclonal heavy chain antibody tislelizumab (HBM4003), in combination with junshi bio (01877.HK)'s anti-PD-1 antibody toripalimab, for the treatment of advanced melanoma and other solid tumors have been recently published.

Research data shows that the combination therapy of tislelizumab and anti-PD-1 antibody in the treatment of solid tumors is safe and manageable, with no new safety signals. Preliminary study results have also found that this combination therapy has shown good anti-tumor activity against solid tumors, especially in mucosal melanoma treated with anti-PD-1 as initial therapy. The clinical study was conducted in two stages with dose escalation and dose expansion, involving a total of 40 patients, aimed at evaluating the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of the combination therapy.

BeiGene Limited's founder, chairman, and CEO, John Oyler, stated that the combination therapy of tislelizumab and anti-PD-1 antibody has shown positive results in a Phase I clinical study, demonstrating good safety and preliminary efficacy. He looks forward to advancing further research to explore the potential of this therapy in addressing unmet medical needs in the current field.